ArticleClinical cancer research : an official journal of the American Association for Cancer Research2011

Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib.

Geoffrey R Oxnard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.